Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer
University of Pittsburgh
University of Pittsburgh
Eli Lilly and Company
University of Wisconsin, Madison
University of Wisconsin, Madison
Washington University School of Medicine
Massachusetts General Hospital
Bayer
M.D. Anderson Cancer Center
Seagen Inc.
Boehringer Ingelheim
University of Arizona
M.D. Anderson Cancer Center
Stanford University
Sichuan Baili Pharmaceutical Co., Ltd.
Bristol-Myers Squibb
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Eli Lilly and Company
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Wake Forest University Health Sciences
All India Institute of Medical Sciences
Mayo Clinic
Boehringer Ingelheim
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Providence Health & Services
Astellas Pharma Inc
National Institutes of Health Clinical Center (CC)
Janssen Pharmaceutical K.K.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Mayo Clinic
National Cancer Institute (NCI)
Eli Lilly and Company
Providence Health & Services
National Cancer Center Hospital East
OncoC4, Inc.
GlaxoSmithKline